Current issues around the pharmacotherapy of ADHD in children and adults
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: New drugs and new formulations enter the growing market for ADHD medication. The growing awareness of possible persistence of ADHD impairment beyond childhood and adolescence resulting in increased pharmacotherapy of ADHD in adults, is also a good reason for making an inventory of the what is generally known about pharmacotherapy in ADHD. AIM: To discuss current issues in the possible pharmacotherapy treatment of ADHD in children, adolescents and adults with respect to the position of pharmacotherapy in ADHD treatment guidelines, the pharmacoepidemiological trends, and current concerns about the drugs used. METHODS: A search of the literature with an emphasis on the position of pharmacotherapy in ADHD treatment guidelines, the pharmacoepidemiological trends, and current concerns about the drugs used in pharmacotherapy. RESULTS: According to the guidelines, the treatment of ADHD in children consists of psychosocial interventions in combination with pharmacotherapy when needed. Stimulants are the first-choice drugs in the pharmacological treatment of ADHD in children despite a number of well known and frequently reported side effects like sleep disorders and loss of appetite. With regard to the treatment of adults, stimulant treatment was recommended as the first-choice pharmacotherapy in the single guideline available. Both in children and adults, there appears to be an additional though limited role for the nonadrenergic drug atomoxetine. The increase of ADHD medication use, in children, adolescents and in adults, can not only be interpreted as a sign of overdiagnosis of ADHD. Despite the frequent use of stimulants, there is still a lack of clarity on the effects of long-term use on growth and nutritional status of children. Cardiovascular effects of both stimulants and atomoxetine are rare but can be severe. The literature suggests that atomoxetine may be associated with suicidal ideation in children. CONCLUSION: Although pharmacotherapy is increasing common in the treatment of ADHD in both children and adults, there are still a lot of questions about side effects and how best to counter them. This suggests an important role for close monitoring of children and adults treated with stimulants or atomoxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“Depending on clinical measures used and the way diagnostic criteria were applied in different studies, the prevalence of ADHD in adults is estimated 1–4% [12–15].”
Method(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863 · cited 1×
“During the 90s, a rapid increase of stimulant use was noticed in several western countries [30–35].”
BackgroundBiederman, J., Mick, E., Faraone, S. V., Braaten, E., Doyle, A., Spencer, T., Wilens, T. E., Frazier, E., & Johnson, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.36 · Cited by 863
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824 · cited 1×
“In a recent literature review [55] reasons for use, misuse and diversion of stimulants include to concentrate, improve alertness, ‘get high’, or to experiment.”
BackgroundRASMUSSEN, P., & GILLBERG, C. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200011000-00017 · Cited by 728 · cited 1×
“Different studies suggest that between one-third and two-thirds of children with ADHD will continue to have disabling symptoms as adults [6–9].”
BackgroundEuropean clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682 · cited 1×
“Since most ADHD children have comorbid disorders, combination of different treatment modalities is usually indicated [16, 17, 19].”
BackgroundKessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663 · cited 1×
“Different studies suggest that between one-third and two-thirds of children with ADHD will continue to have disabling symptoms as adults [6–9].”
BackgroundMTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
WENDER, P. H., WOLF, L. E., & WASSERSTEIN, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05770.x · Cited by 498
Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999) · Pediatrics · doi:10.1542/peds.104.2.e20 · Cited by 493
SANDRA KOOIJ, J. J., BUITELAAR, J. K., van den OORD, E. J., FURER, J. W., TH. RIJNDERS, C. A., & HODIAMONT, P. P. G. (2005) · Psychological Medicine · doi:10.1017/s003329170400337x · Cited by 468 · cited 1×
“Depending on clinical measures used and the way diagnostic criteria were applied in different studies, the prevalence of ADHD in adults is estimated 1–4% [12–15].”
MethodEffect of Melatonin on Sleep, Behavior, and Cognition in ADHD and Chronic Sleep-Onset Insomnia
VAN der HEIJDEN, K. B., SMITS, M. G., VAN SOMEREN, E. J. W., RIDDERINKHOF, K. R., & GUNNING, W. B. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000246055.76167.0d · Cited by 378
de Graaf, R., Kessler, R. C., Fayyad, J., ten Have, M., Alonso, J., Angermeyer, M., Borges, G., Demyttenaere, K., Gasquet, I., de Girolamo, G., et al. (2008) · Occupational and Environmental Medicine · doi:10.1136/oem.2007.038448 · Cited by 355
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336 · cited 1×
“[27], effects of atomoxetine and osmotically released methylphenidate were compared with placebo.”
BackgroundEffect of Stimulants on Height and Weight: A Review of the Literature
Faraone, S. V., Biederman, J., Morley, C. P., & Spencer, T. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.obo13e31817eoea7 · Cited by 286
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2003) · Pediatrics · doi:10.1542/peds.111.1.97 · Cited by 274
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00006 · Cited by 191
Evaluating the Evidence For and Against the Overdiagnosis of ADHD
Sciutto, M. J., & Eisenberg, M. (2007) · Journal of Attention Disorders · doi:10.1177/1087054707300094 · Cited by 186 · cited 1×
“Sciutto and Eisenburg evaluated the evidence for and against overdiagnosis of ADHD [50].”
BackgroundGraham, J., & Coghill, D. (2008) · CNS Drugs · doi:10.2165/00023210-200822030-00003 · Cited by 185
KOOIJ, J. J. S., BURGER, H., BOONSTRA, A. M., VAN DER LINDEN, P. D., KALMA, L. E., & BUITELAAR, J. K. (2004) · Psychological Medicine · doi:10.1017/s0033291703001776 · Cited by 163 · cited 1×
“In a recent 6week study by Newcom et al. [ 27 ], effects of atomoxetine and osmotically released methylphenidate were compared with placebo.”
BackgroundWeisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., Read, S. C., & Tulloch, S. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900013687 · Cited by 158
Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152
Growth on stimulant medication; clarifying the confusion: a review
Poulton, A. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.056952 · Cited by 129
Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?
SPENCER, T. J., FARAONE, S. V., BIEDERMAN, J., LERNER, M., COOPER, K. M., & ZIMMERMAN, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205710.01690.d4 · Cited by 125
Stimulant Treatment Over 5 Years: Effects on Growth
CHARACH, A., FIGUEROA, M., CHEN, S., ICKOWICZ, A., & SCHACHAR, R. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000199026.91699.20 · Cited by 119 · cited 1×
“The slight reduction in height and weight seems to be dose related [62].”
BackgroundPLISZKA, S. R., MATTHEWS, T. L., BRASLOW, K. J., & WATSON, M. A. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205702.48324.fd · Cited by 106 · cited 1×
“The effect of drug holidays to reduce growth effects of stimulants is ambiguous [63, 64].”
Background
Cited by
Autism and ADHD: how far have we come in the comorbidity debate
Gargaro, B. A., Rinehart, N. J., Bradshaw, J. L., Tonge, B. J., & Sheppard, D. M. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.11.002 · Cited by 244
“The best known treatment for a child with ADHD is stimulant edication; this type of intervention has been shown to be more ffective than non-pharmacological interventions alone at reducng the core symptoms (Meijer et al., 2009; Brown et al., 2005; he MTA Cooperative Group, 1999a,b).”
BackgroundDistinguishing comorbidity and successful management of adult ADHD
Kooij, J. J. S., Huss, M., Asherson, P., Akehurst, R., Beusterien, K., French, A., Sasané, R., & Hodgkins, P. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711435361 · Cited by 172
Abramovitch, A., Dar, R., Mittelman, A., & Wilhelm, S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000050 · Cited by 120
(2011) · PubMed · Cited by 77
The Role of Sleep Dysfunction in Physical Inactivity and its Relationship to Obesity
Watenpaugh, D. E. (2009) · Current Sports Medicine Reports · doi:10.1249/jsr.0b013e3181c27834 · Cited by 29
“This connection informs the logic behind use of stimulant medications (‘‘You’re prescribing my son what?’’) to reduce hyperactivity in children (42).”
Background
Metadata
- Authors
- Meijer, W. M., Faber, A., den Ban, E., & Tobi, H.
- Venue
- Pharmacy World & Science
- Published
- 2009-06-27
- Volume
- 31
- Issue
- 5
- Pages
- 509-516
- ISSN
- 0167-6555 (ISSN-L)
- 0928-1231
- 1573-739X
- OpenAlex
- W2161562332
- Cited by
- 52
- References
- 33
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.